Showing 20 of 120 recruiting trials for “Small cell lung cancer”
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
👨⚕️ Dingzhi Huang, M.D., Tianjin Medical University Cancer Institute and Hospital📍 2 sites📅 Started May 2024View details ↗
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecruitingNCT07288632 ↗
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
👨⚕️ Jingfang Mao, PHD, Shanghai Proton and Heavy Ion Center📍 1 site📅 Started Dec 2023View details ↗
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
👨⚕️ Revolution Medicines, Inc., Revolution Medicines, Inc.📍 53 sites📅 Started Nov 2023View details ↗
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
RecruitingNCT06160596 ↗
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
👨⚕️ Julieta Rodriguez, MD, Gustave Roussy, Cancer Campus, Grand Paris📍 1 site📅 Started Nov 2023View details ↗
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →